

**CHEMICAL STABILITY OF
PHARMACEUTICALS**
A HANDBOOK FOR PHARMACISTS

KENNETH A. CONNORS

School of Pharmacy, The University of Wisconsin

GORDON L. AMIDON

School of Pharmacy, The University of Wisconsin

LLOYD KENNON

*Formerly School of Pharmacy,
The University of Wisconsin*

A WILEY-INTERSCIENCE PUBLICATION

JOHN WILEY & SONS

NEW YORK • CHICHESTER • BRISBANE • TORONTO

Copyright © 1979 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

Library of Congress Cataloging in Publication Data:

Connors, Kenneth Antonio, 1932-
Chemical stability of pharmaceuticals.

"A Wiley-Interscience publication."

Includes bibliographical references and index.

1. Drug stability. I. Amidon, Gordon L., joint author. II. Kennon, Lloyd, 1929- joint author.
- III. Title. [DNLM: 1. Drug stability--Handbooks. 2. Kinetics--Handbooks. QV38 C572c]

RS189.C628 615'.19 78-1759
ISBN 0-471-02653-0

Printed in the United States of America.

10 9 8 7 6 5 4 3 2 1

CHAPTER 5

Oxidation

On and within a few miles of the earth's surface, oxygen is the most abundant of elements. It makes up about 46% of the earth's crust and, of course, 89% of the water and over 20% of the air. It is the last component that causes many of our pharmaceutical problems. With so much oxygen around, it is no wonder that oxidation reactions, both completed and potential, are omnipresent. Ironically, virtually all of our useful drugs exist in a reduced, not their most oxidized, form; it is clear, then, that "the battle is on."

Whereas in hydrolytic reactions temperature, pH, and the presence of water are the major factors that influence drug decomposition, oxidative reactions are strongly influenced by environmental factors such as light and metal ions, in addition to, of course, oxygen and oxidizing agents. For example, 0.0002 M copper has been shown to increase the rate of ascorbic acid oxidation by a factor of 10,000 over that in the absence of copper. One of the major problems encountered in dealing with oxidation reactions is that some reactants such as oxygen or metal ion need not be present in more than trace quantities to produce significant stability problems. Another interesting aspect of oxidative decomposition is the tendency of many drugs to form colored products and various other formulation components to produce off-odors. Consequently, although only a very low level of oxidative degradation may have occurred, with drug decomposition being insignificant both chemically and therapeutically, the drug product may nevertheless be rejected and not used. Finally, note that oxidation can occur in both aqueous and non-aqueous solutions as well as in the solid state to some extent.

A. NATURE OF OXIDATION

When one considers oxidation, it is important to

stability problems will arise from light of the shorter wavelengths, in particular from the short visible and the UV.

When electromagnetic radiation is absorbed, essentially only one of four events occurs:

1. The absorbing molecule decomposes.
2. The energy is either retained until it can be used chemically or is transferred to another molecule, which may or may not decompose.
3. The energy is converted to heat, and no reaction ensues.
4. The absorbing molecule emits light of a different wavelength (fluorescence or phosphorescence), and no decomposition occurs.

The work to be described now illustrates by means of a specific example the very marked, explicit effect of UV light on an oxidative reaction. Solutions (5%) of two therapeutically useful phenothiazine salts, chlorpromazine hydrochloride and prochlorperazine ethanedisulfonate, were placed in a Warburg respirometer to permit measurement of oxygen uptake and were then exposed to a sunlamp. [The structure of chlorpromazine is given in Eq. (5.21); prochlorperazine is similar, with the dimethylamino group being replaced by 4-methyl-1-piperazinyl.] The solutions became colored shortly after the light was turned on, and they continued to darken. The data (1) are shown graphically in Figure 5.1.

C. INHIBITION OF OXIDATION

1. Protection from Light

As previously described, many compounds undergo changes on receiving and absorbing radiant energy (light). When one is dealing with pharmaceutical products, any alterations, light-induced or otherwise, that result in losses in potency or in color or taste changes are detrimental. Therefore, the choice of a suitable container is very important. At the outset of this discussion it is stressed that whatever container




FIGURE 5.1. Plot of oxygen-uptake data for chlorpromazine hydrochloride (A) and prochlorperazine ethanedi-sulfonate (B) illustrating induction period, the linearity of the uptake with time, and the extreme light dependence of the oxidative degradation (1).

is chosen, it must be tested with the formula it is to hold to ascertain the overall stability characteristics. Although most such testing is done in industrial laboratories, and although the community pharmacist certainly would not dispense a moisture-sensitive product in a cardboard box, he should appreciate this fact since he does do some repackaging. Note also that if a product is light-sensitive, it is important that this fact be stated on the label.

To exclude light, four main techniques are available: (a) wrap-around labels, (b) container coatings (some may incorporate ultraviolet absorbing materials), (c) various cartoning procedures, and (d) the use of so-called light-resistant containers. Since the latter are mentioned in the United States Pharmacopeia (2), we treat this area in some detail.

The light-transmission limits of glass and plastic containers are specified by the USP (2). These limits

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.